Geron

GERN

Market cap $1.07B

Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European pricing negotiations suggest a more cautious outlook for RYTELO's global commercial expansion.

Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.

Geron Corporation (GERN) Q4 2025 Earnings Call Transcript

Achieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the previous guidance range Reiterated 2026 RYTELO net product revenue and total operating expenses expected in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended 2025 with cash, cash equivalents, restricted cash and marketable securities of roughly $401 million Company to host conference call and webcast today, February 25, at 8:00 a.m. ET FOSTER CITY, Calif.

FOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to present at the following investor conferences:

FOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to purchase an aggregate of 742,500 shares of common stock to one newly hired employee as an inducement material to such employee's acceptance of employment with Geron.

As of Feb. 18, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. GERN announced a restructuring in December and gave some financial guidance in January, including guidance for 2026 Rytelo net product revenues of $220M-$240M. GERN's IMpactMF study of imetelstat in myelofibrosis is expected to reach an interim analysis in 2026; the existence of that interim could trigger a run-up in the stock.

2026 RYTELO ® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined operations to support path toward building a sustainable hematology company FOSTER CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, aiming to change lives by changing the course of blood cancer, today announced 2026 financial guidance.